01. Investing
Hillman Ventures.
Private family office investing in frontier biotech. Three priorities. Inflammation. Damaged tissue. Tumor-based cancers. Capital allocated with operator judgment behind it.
hillmanv.comDallas, Texas • Hillman Ventures, est. 1995
Leadership. Strategy. Growth.
Principal of Hillman Ventures. Three decades in FDA-regulated healthcare. Frontier biotech, regulatory strategy, and Dallas philanthropy.
Request a ConversationPractice
What I do, today.
02. Writing
The Hillman Letter.
Essays on FDA regulatory strategy, biotech investment thesis, and capital allocation discipline at family offices. Ships from Dallas. Short, direct, sourced.
Read latest03. Advising
Strategic Counsel.
Pathway review, standing retainer, board director or observer, and investor diligence support for FDA-regulated biotech operators and family office allocators.
andrewhillmanadvisor.com04. Expert Witness
Healthcare Compliance.
Expert witness in federal and state civil matters where the regulatory record is the central question. Limited engagements per year. Inquiry by invitation.
andrewjhillman.comApproach
Thirty years of FDA-regulated work, compressed into one operating philosophy.
"Manufacturing decisions follow product lock. Headcount follows revenue or paid clinical milestones. Regulatory strategy precedes site selection. These are not slogans. They are filters."
Hillman Ventures was founded in Dallas in 1995. The original mandate was simple. Invest in FDA-regulated healthcare ventures where the science is real, the regulatory pathway is defensible, and the operators can absorb agency guidance at the cadence the science requires. Three decades on, that mandate has not changed.
The portfolio today concentrates on frontier biotech. Inflammation and damaged-tissue regeneration. Targeted oncology mechanisms that reach tumors small molecules and immunotherapies do not. Exosome biologics on the 351(a) pathway. Cell and gene therapy programs where the manufacturing process is the product.
The work outside the portfolio is the work that shaped the inside. The Hillman Letter on FDA regulatory strategy. The Andrew Hillman Scholarship for Entrepreneurs and the Andrew Hillman Grant for Biotech at Southern Methodist University. The Andrew Hillman Family Room at the Lamplighter School.
— ⋄ —
In biologics, the process is the product. Locking process before product is the most common capital destruction event I see in this category.Andrew Jonathan Hillman · Principal, Hillman Ventures
Properties
The full operating footprint.
Hillman Ventures
Family office. FDA-regulated frontier biotech since 1995.
hillmanv.com
Hillman Advising
Strategic advisory. Regulatory pathway. Board director and observer.
andrewhillmanadvisor.com
Andrew J. Hillman
Expert witness practice in healthcare compliance.
andrewjhillman.com
The Hillman Letter
Essays on FDA regulatory strategy and capital discipline.
thehillmanletter.substack.com
FixCancer.org
Targeted Osmotic Lysis. Patient navigation for advanced solid tumor cancers.
fixcancer.org
The Public Record
Primary sources. Maintained for full transparency.
andrewhillmanrecord.com
A complete public record. Primary sources.
Maintained as a matter of practice. Anyone deciding whether to take a call, sit on a board, or invest alongside Hillman Ventures may read the primary record directly.
Visit the public record